We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 11, 2019

A Risk-Based Treatment Strategy for Non-Rhabdomyosarcoma Soft-Tissue Sarcomas in Young Patients

The Lancet Oncology

 

Additional Info

The Lancet Oncology
A Risk-Based Treatment Strategy for Non-Rhabdomyosarcoma Soft-Tissue Sarcomas in Patients Younger Than 30 Years (ARST0332): A Children's Oncology Group Prospective Study
Lancet Oncol 2019 Nov 27;[EPub Ahead of Print], SL Spunt, L Million, YY Chi, J Anderson, J Tian, E Hibbitts, C Coffin, MB McCarville, RL Randall, DM Parham, JO Black, SC Kao, A Hayes-Jordan, S Wolden, F Laurie, R Speights, E Kawashima, SX Skapek, W Meyer, AS Pappo, DS Hawkins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading